ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CSL Behring Begins Trial to Evaluate Monoclonal Antibody for Respiratory Distress
July 16, 2020CSL Behring announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress ... -
In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
July 07, 2020Global biotherapeutics leader CSL Behring announced that the first patient has been enrolled in its Phase 2 study to assess the safety and efficacy of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from ...
Pharma Sources Insight January 2025
